📇 Rhumatologue · LE PORT MARLY · (78) · Salarié

M MEHRAN KHATIBI-NOURI

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
86.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LE PORT MARLY (78)SalariéRPPS 10001404689

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

ONCOPOP
CHP DE L'EUROPE 9 BIS AVENUE DE SAINT GERMAIN, 78560 LE PORT MARLY
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease

European journal of preventive cardiology · 2026

📚 9 citations🎯 RCR 9.00🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Aims Identifying alternative contributors to the residual risk of atherosclerotic cardiovascular disease (ASCVD) beyond LDL cholesterol (LDL-C) levels is crucial. We investigated the relative impact of triglycerides (TGs) and high-sensitivity C-reactive protein (hs-CRP) on outcomes in statin-treated patients with well-controlled LDL-C undergoing percutaneous coronary intervention (PCI) for established ASCVD. Methods and results We included 9446 statin-treated patients with LDL-C &lt; 70 mg/dL undergoing PCI between 2012 and 2022, stratified into four groups: (i) no residual risk (TG &lt;150 mg/dL + hs-CRP &lt;2 mg/L); (ii) residual TG risk (TG ≥150 mg/dL + hs-CRP &lt;2 mg/L); (iii) residual inflammatory risk (TG &lt;150 mg/dL + hs-CRP ≥2 mg/L); and (iv) residual TG and inflammatory risk (TG ≥150 mg/dL + hs-CRP ≥2 mg/L). The primary endpoint was major adverse cardiovascular events (MACE) at 1 year, consisting of all-cause mortality, myocardial infarction, or stroke. Cox regression analysis was performed, using the no residual risk group as a reference. Of the total population, 5339 (56.5%) had no residual risk, 555 (5.9%) presented residual TG risk, 3009 (31.9%) had residual inflammatory risk, and 543 (5.7%) exhibited residual combined risk. After multivariable adjustment, patients with residual inflammatory or combined risk showed a significantly higher hazard of MACE, mainly driven by all-cause mortality. No significant difference was observed between patients with residual TG risk and those with no residual risk. Conclusion In statin-treated patients with well-controlled LDL-C undergoing PCI, residual inflammatory risk—alone or in combination with residual TG risk—was associated with a higher incidence of MACE, highlighting the need for targeted preventive strategies beyond LDL-C lowering.

Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysis

European heart journal · 2026

📚 8 citations🎯 RCR 8.00

Lire l'abstract Crossref ↓

Abstract Background and Aims Dual antiplatelet therapy (DAPT) de-escalation strategies improve outcomes after percutaneous coronary intervention (PCI) compared to standard DAPT. However, the potential impact of sex on the safety and efficacy of these strategies is yet to be fully investigated. Methods Randomized controlled trials comparing de-escalated vs standard DAPT regimens in patients without baseline indication for oral anticoagulation reporting outcomes stratified by sex were included. The co-primary endpoints were trial-defined major adverse cardiovascular events (MACE) and major bleeding. Hazard ratios (HR) with 95% confidence intervals (CI) were computed to account for different follow-up durations. A network meta-analysis including ranking of treatments was performed to explore the comparative effects of different DAPT de-escalation strategies among females and males. Results Overall, 71 272 patients from 20 trials were included, and 23.3% were female. De-escalation strategies were grouped into (1) DAPT discontinuation, by aspirin or the P2Y12 inhibitor; or (2) P2Y12 inhibitor switch or dose reduction. With DAPT discontinuation vs standard DAPT, a significant interaction between treatment effect and sex was found for both MACE (Pint = .028) and major bleeding (Pint = .015). Indeed, DAPT discontinuation reduced MACE in females (HR, 0.86; 95% CI, 0.75–0.98) but not in males (HR, 1.04; 95% CI 0.93–1.16), while reducing major bleeding in males (HR, 0.60; 95% CI, 0.44–0.82) but not in females (HR, 1.04; 95% CI, 0.76–1.43), compared to standard DAPT. Conversely, no interactions by sex were found with P2Y12 inhibitor switch or dose reduction vs standard DAPT for both MACE (Pint = .668) and major bleeding (Pint = .858). At treatment ranking, aspirin discontinuation ranked best for most outcomes in females, while P2Y12 inhibitor switch to clopidogrel showed the best outcomes in males. Conclusions Sex may influence the safety and efficacy of antiplatelet de-escalation strategies after PCI, particularly those involving the shortening of DAPT. Aspirin discontinuation may represent the optimal strategy for females, while P2Y12 inhibitor switch to clopidogrel may be most effective for males.

Impact of lesion location and SYNTAX score breakdown on patients undergoing percutaneous left main revascularization

Cardiovascular revascularization medicine : including molecular interventions · 2026

📚 2 citations

Cookies & analyse de trafic

M MEHRAN KHATIBI-NOURI

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Transversal11

Essai clinique5

IA en rhumatologie2

Qualité de vie / PROMs2

Revue / méta-analyse2

Revue générale2

Risque cardio-vasculaire2

Économie santé1

Épidémiologie & registres1

Santé mentale / fatigue1

Partager cette fiche